March 16 (Reuters) - Arcus Biosciences Inc :
* ARCUS BIOSCIENCES INC - HAS DOSED FIRST SUBJECT IN ARC-10, A PHASE 3 STUDY
* ARCUS BIOSCIENCES - DOSING OF FIRST SUBJECT TRIGGERS MILESTONE PAYMENTS TO WUXI BIOLOGICS OF $10 MILLION AND ABMUNO THERAPEUTICS OF $5 MILLION
* ARCUS BIOSCIENCES INC - WILL OWE A SUBSEQUENT MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 TRIAL IN A SECOND INDICATION
Source text: () Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* ARCUS BIOSCIENCES INC - HAS DOSED FIRST SUBJECT IN ARC-10, A PHASE 3 STUDY
* ARCUS BIOSCIENCES - DOSING OF FIRST SUBJECT TRIGGERS MILESTONE PAYMENTS TO WUXI BIOLOGICS OF $10 MILLION AND ABMUNO THERAPEUTICS OF $5 MILLION
* ARCUS BIOSCIENCES INC - WILL OWE A SUBSEQUENT MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 TRIAL IN A SECOND INDICATION
Source text: () Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)